Xenon to Present at BofA Securities 2024 CNS Therapeutics Virtual Conference

Rhea-AI Summary

Xenon Pharmaceuticals (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, announced its participation in the upcoming BofA Securities 2024 CNS Therapeutics Virtual Conference on October 7, 2024. The company will present a fireside chat at 11:40 am Eastern Time, with a live webcast available on Xenon's website.

Xenon is dedicated to discovering, developing, and delivering life-changing therapeutics for patients with neurological and psychiatric disorders. Their novel product pipeline focuses on areas of high unmet medical need, including epilepsy and depression. The company's lead product, azetukalner, is a Kv7 channel opener in late-stage clinical development for multiple indications, representing the most advanced, clinically validated potassium channel modulator.

VANCOUVER, British Columbia and BOSTON, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced its participation in the upcoming BofA Securities 2024 CNS Therapeutics Virtual Conference taking place October 7, 2024.

Fireside Chat Presentation Details:
Date:	Monday, October 7, 2024
Time:	11:40 am Eastern Time
Webcast:	Register here

A live webcast of the company presentation will be available on the “Investors” section of Xenon’s website and posted for replay following the event. The above listed dates and times are subject to change.

About Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals (Nasdaq:XENE) is a neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing innovative therapeutics to improve the lives of people living with neurological and psychiatric disorders. We are advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, our lead Kv7 channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. For more information, please visit www.xenon-pharma.com.

“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.

Contacts:
For Investors:
Chad Fugere
Vice President, Investor Relations
(857) 675-7275
investors@xenon-pharma.com

For Media:
Colleen Alabiso
Senior Vice President, Corporate Affairs
(617) 671-9238
media@xenon-pharma.com

FAQ

When is Xenon Pharmaceuticals (XENE) presenting at the BofA Securities 2024 CNS Therapeutics Virtual Conference?

Xenon Pharmaceuticals (XENE) is presenting at the BofA Securities 2024 CNS Therapeutics Virtual Conference on Monday, October 7, 2024, at 11:40 am Eastern Time.

What is Xenon Pharmaceuticals' (XENE) main focus in drug development?

Xenon Pharmaceuticals (XENE) focuses on discovering, developing, and delivering therapeutics for neurological and psychiatric disorders, with a particular emphasis on epilepsy and depression.

What is azetukalner and what is its significance for Xenon Pharmaceuticals (XENE)?

Azetukalner is Xenon Pharmaceuticals' (XENE) lead product. It is a Kv7 channel opener in late-stage clinical development for multiple indications and represents the most advanced, clinically validated potassium channel modulator.

How can investors access Xenon Pharmaceuticals' (XENE) presentation at the BofA Securities conference?

Investors can access a live webcast of Xenon Pharmaceuticals' (XENE) presentation on the 'Investors' section of the company's website. The webcast will also be available for replay after the event.